.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,419,973

« Back to Dashboard
Patent 7,419,973 protects TEFLARO and is included in one NDA. There has been one Paragraph IV challenge on Teflaro.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 7,419,973

Title:Phosphonocephem compound
Abstract:A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH.sub.3COOH, CH.sub.3CH.sub.2COOH or CH.sub.3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like. ##STR00001##
Inventor(s): Ishikawa; Tomoyasu (Shiga, JP), Hashiguchi; Shohei (Osaka, JP), Iizawa; Yuji (Kyoto, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/063,715
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 6th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXNo7,419,973► subscribeY
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-002Oct 29, 2010RXYes7,419,973► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,419,973

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-247966Aug 10, 2000
Japan2000-354959Nov 21, 2000

Non-Orange Book Patents for Patent: 7,419,973

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,906,055 Phosphonocephem compound► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,419,973

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1310502► subscribe
South Korea100826487► subscribe
South Korea20030022891► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc